Ann: Antisense Therapeutics transitions to new Board Chair, page-15

The announcement is self explanatory but a few things stood out to me.

Firstly, they describe themselves as a “ late stage clinical development GROUP”.. the word ‘group’ is quite profound. In business legal terms, the use of group usually means independent legal entities. I have mentioned in the past that the smart play for the larger diseases would be to do this as a partnership / collaboration with a major. i used CSL as an example with a 50/50 JV with CSL putting in $500m and ANP putting in the IP.. or something along those lines. The word group could mean many things but it does imply significant changes / progress is afoot.

They also talk of pipeline development and commercialisation initiatives separately. With the coming presentation of the Mode of Action and Biological Activity at a conference later this year, I feel like the market is grossly underestimating what is occurring behind the scenes.

It feels like this may be a very different looking company by Xmas with the first major move announced today.